Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Extension Study of ARGX-113-2009 to Evaluate the Long Term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid

NCT05681481 is registered in ClinicalTrials.gov with argenx as lead sponsor.

NCT NCT05681481
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05681481 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Extension Study of ARGX-113-2009 to Evaluate the Long Term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid
Lead sponsor
argenx
Phase
Phase 3
Overall status
Terminated
Start date
March 22, 2023
Completion date
March 20, 2025
Enrollment
64 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

bullous pemphigoid